Summary

Patients with rheumatoid arthritis (RA) who are treated with adalimumab plus methotrexate (MTX) have higher serum trough levels of adalimumab and a better clinical response to therapy than patients treated with adalimumab alone [Pouw MF et al. Ann Rheum Dis 2013]. This article discusses the effect on adalimumab serum concentrations in patients with RA or psoriatic arthritis taking concomitant MTX and concomitant disease-modifying antirheumatic drugs (DMARDs) other than MTX.